Physician profile
Steven Zuckerman
NPI 1972559698
$694.55
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $96.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $153.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $128.04 | 2019 | |
| Daiichi Sankyo INC. | $77.32 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $45.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.88 | 2019 | |
| Mdd US Operations, LLC | $41.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.85 | 2019 | |
| Sk Life Science, INC. | $30.18 | 2020 | |
| Supernus Pharmaceuticals, INC. | $28.44 | 2019 | |
| Ucb, INC. | $22.70 | 2020 | |
| Eusa Pharma (US) LLC | $22.26 | 2019 | |
| Genzyme Corporation | $20.62 | 2019 | |
| Acadia Pharmaceuticals INC | $20.18 | 2019 | |
| Lilly USA, LLC | $11.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Zuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.